Serum's Bilthoven acquisition opens door to cut-price polio vaccine in Europe and US
This article was originally published in Scrip
Serum Institute's acquisition of the government-owned Dutch manufacturer of monoclonal antibodies and vaccines, Bilthoven Biologicals, is expected to change the market dynamics for injectable polio vaccines, the capability and technology for which is currently vested in just three global facilities. The buyout will also provide the Indian firm with a manufacturing foothold in the West, boosting its plans to expand into Europe and the US.
You may also be interested in...
Panacea Biotec has allied with the world’s largest-vaccine maker, the Serum Institute of India, to ramp up production of a six-in-one jab aimed at preventing killer diseases like polio and diphtheria and target a global market estimated to be worth over $1.25bn annually.
Syngene’s COO, Mahesh Bhalgat, said the firm is better placed than some peers to serve clients for biologics-based advanced therapies and address the cost element for new modalities like mRNA. He also outlines the research, development and manufacturing services company's capabilities in oligonucleotide-based therapeutics, an area that's seeing growing interest.
Glenmark’s innovation subsidiary, Ichnos, highlights encouraging early data for lead bispecific antibody assets and hopes to accelerate these via licensing and partnership deals.The US-based arm also points to the tough biopharma financing market where investors are no longer satisfied with just the “preclinical story”.